Abstract: Transcriptome-wide association studies integrate gene expression data with common risk variation to identify gene-trait associations. By incorporating epigenome data to estimate the functional importance of genetic variation on gene expression, we improve the accuracy of transcriptome prediction and the power to detect significant expression-trait associations. Joint 5 analysis of 14 large-scale transcriptome datasets and 58 traits identify 13,724 significant expression-trait associations that converge to biological processes and relevant phenotypes in human and mouse phenotype databases. We perform drug repurposing analysis and identify known and novel compounds that mimic or reverse trait-specific changes. We identify genes that exhibit agonistic pleiotropy for genetically correlated traits that converge on shared biological 10 pathways and elucidate distinct processes in disease etiopathogenesis. Overall, this comprehensive analysis provides insight into the specificity and convergence of gene expression on susceptibility to complex traits. 15 20 Despite the recent success of genome-wide association studies (GWASs) in cataloguing risk genetic variation, our understanding of the mechanisms through which they act remain largely unknown 1 . Risk variants are highly enriched in cis regulatory elements (CREs), including promoters and enhancers 2, 3 and affect the regulation of gene expression [2] [3] [4] [5] [6] [7] [8] [9] [10] . Multiple computational methods have been developed to link risk variants with differential gene 5 expression [11] [12] [13] [14] [15] . PrediXcan 16 performs transcriptome-wide association study (TWAS) by gene expression imputation, and so far it outperforms similar methods 17 . Briefly, PrediXcan uses elastic net (ENet) regression models, trained in a reference transcriptome, to impute gene expression. The models use a set of cis-SNPs (SNPs in proximity to the transcription start site) as linear predictors of gene expression. The imputed expressions are then correlated with the 10 phenotype of interest to identify gene-trait associations (GTAs).
Here we present EpiXcan, a novel method that increases prediction accuracy in transcriptome imputation by integrating epigenetic data to model the prior probability that a SNP affects transcription. EpiXcan specifically leverages annotations derived from the Roadmap 15 Epigenomics Mapping Consortium (REMC) that integrates multiple epigenetic assays, including DNA methylation, histone modification and chromatin accessibility 18 . The rationale of our approach is that SNPs within CREs are more likely to be functionally relevant 19 . We then utilize 14 large-scale transcriptome datasets of genotyped individuals to train prediction models and integrate with 58 complex traits and diseases to define significant GTAs. GTAs exhibit 20 significant enrichment for relevant biological pathways and known genes linked to trait-related phenotypes in humans and mice. Imputed transcriptomic changes are used to identify known compounds that can normalize genetically driven expression perturbations. Pairwise trait analysis identifies genes that exhibit agonistic pleiotropy for genetically correlated traits that converge on shared biological pathways. Finally, bi-directional regression analysis identifies 25 putative causal relationships among traits. Overall, our analysis provides insight into the specificity and convergence of gene expression mediating the genetic risk architecture underlying susceptibility of complex traits and diseases.
Results
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EpiXcan outperforms PrediXcan
Since TWAS is limited to genes that can be accurately predicted from genotype data, increasing prediction accuracy can increase the scope and power of analyses. Here, we integrate biologically relevant data in a single framework to improve performance of gene expression 35 prediction. The overall schematic of EpiXcan is shown in Supplementary Fig. 1 . Briefly, EpiXcan leverages epigenetic annotation to inform transcriptomic imputation by employing a three-step process (Online methods and Supplementary Methods): (1) estimate SNP priors that reflect the likelihood of a SNP having a regulatory role in gene expression based on a Bayesian hierarchical model 20 that integrates epigenomic annotation 18 and eQTL summary 40 statistics for cis-SNPs (SNPs located ± 1 Mb from the transcription start site of the gene); (2) rescale the SNP priors to penalty factors by employing a novel adaptive mapping approach; and (3) use the genotypes and penalty factors in weighted elastic net to perform gene expression prediction.
Using simulated data, we apply EpiXcan and PrediXcan to train prediction models and estimate the adjusted cross-validation R-squared (R based on one-sample sign test; Supplementary Fig. 2 ). We then train prediction models by applying EpiXcan and PrediXcan in 14 RNAseq datasets, derived from dorsolateral prefrontal cortex (DLPFC) from the CommonMind Consortium (CMC) 21 , seven tissues from StockholmTartu Atherosclerosis Reverse Network Engineering Task (STARNET) 22 and six tissues from GTEx 23 (Supplementary Table 1 (average number of genes across tissues is 9,760). To obtain the second metric, R 2 PP , we train prediction models in the training dataset, which are then used to predict expressions in the test dataset. Across all datasets, EpiXcan improves the average R 2 PP compared to PrediXcan (all p values < 9 × 10 -16 based on one-sample sign test; Fig. 1; Supplementary Fig. 4 ; Supplementary Table 3) . Importantly, the ratios of genes predicted more effectively by 25 EpiXcan than PrediXcan are higher in the independent dataset evaluation (R 2 PP ) than in the cross-validation (unpaired t-test, p value = 3.3 × 10 -17 ) (Fig. 1) , suggesting that the adaptive rescaling of the penalty factors during model training does not result in significant overfitting that could affect the external validity of the models. Overall, compared to PrediXcan, EpiXcan has improved predictive performance and identifies more genes that can be used for TWAS. Positive and negative delta values indicate genes with higher predictive performance in EpiXcan and PrediXcan, respectively. These genes are assigned as "EpiXcan" and "PrediXcan" and counts are shown as barplots. The number on the right indicates the ratio of "EpiXcan" assigned gene counts divided by "PrediXcan" counts. Across all datasets, the ratios are higher than 1 indicating that EpiXcan outperforms 
EpiXcan informs better gene-trait associations than PrediXcan
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We apply EpiXcan and PrediXcan prediction models from 14 tissues (Supplementary Table 1 ) in 58 complex traits (Supplementary Table 4 ) and examine their performance based on four criteria: the number of GTAs that are: (1) significant after multiple testing correction, (2) novel (significantly associated genes that lie outside the GWAS loci) (3) unique (i.e., genes identified only by one method), and (4) enriched for clinically relevant genes. 15 EpiXcan has more power to detect GTAs than PrediXcan (Kolmogorov-Smirnov p value is 3.3 × 10 -16 ; Fig. 2a ). We observe a 9.6% increase (n = 1,202) in the significant GTAs at 0.01 false discovery rate (FDR) 24 using EpiXcan (n=13,724) compared to PrediXcan (n=12,522). One advantage of PrediXcan/EpiXcan methods is that they identify "novel genes" within loci that did 20 not reach genome-wide significance (p < 5 × 10 -8 ) in GWASs. We detect an 18.3% increase (one sample sign test p value = 3.6 × 10 -6 ) in the novel GTAs using EpiXcan (mean of 25.4) compared to PrediXcan (mean of 21.5) (Supplementary Fig. 5 ). The largest difference is observed for height (EpiXcan = 168, PrediXcan = 134), followed by schizophrenia (EpiXcan = 119, PrediXcan = 104) (Supplementary Fig. 6 ). 25 For any given tissue and trait, we find high correlation of GTA z-scores between EpiXcan and PrediXcan (Pearson's correlation r = 0.92) (Fig. 2b) but overall, we observe unique associations for each method. We identify 79.9% (n=327) more unique genes in EpiXcan (n=788) than PrediXcan (n=461) (Supplementary Fig. 7 ), due to either a lack of a prediction model for a 30 specific gene and/or tissue or insufficient statistical power using PrediXcan models. For example, using the waist-adjusted BMI trait and prediction models from STARNET subcutaneous adipose tissue, overall, we observe high correlation between EpiXcan and PrediXcan genes (Pearson's r = 0.83) (Supplementary Fig. 8 ). Interestingly, EpiXcan identifies 7 genes (PPP2R5A, ALAS1, HOXC8, PIEZO1, SCD, PARP3, EYA1) that are not detected by 35 PrediXcan even if we test across all tissue-specific models. SCD (stearoyl-CoA desaturase) is of particular interest as it codes for an enzyme that catalyzes a rate-limiting step in the synthesis of unsaturated fatty acids (mainly oleate and palmitoleate); knocking out the SCD mouse ortholog gene results in reduced body adiposity and resistance to diet-induced weight gain 25 30 . GTAs from both PrediXcan and EpiXcan exhibit enrichment for genes that are associated with the traits in above datasets 10 ( Supplementary Fig. 9 ).
Transcripts identified by EpiXcan (q value = 0.029), but not by PrediXcan (q value = 0.096), are enriched for genes that are extremely loss-of-function intolerant (pLI ≥ 0.9) (Fig. 2c) . More specifically, we find significant enrichment of pLI genes with neuropsychiatric (q value = 0.012, 15 known association 31, 32 ) and anthropometric/development (q value = 0.032) related traits (Supplementary Table 5 ). Unlike pLI, for all other gene sets (ClinVar, OMIC CS, SoftPanel, MGD), we define and test for enrichment only for that specific trait. For example, for autism, we generate a gene list from the significant autism-specific GTAs from all tissues for each method and perform GSEA for genes in the ClinVar database that are reported to be associated with 20 autism. In so doing, we find that, overall, EpiXcan has more power than PrediXcan to identify clinically relevant genes ( Fig. 2d) including those that are more likely to belong to more than one dataset (pLI, ClinVar, OMIC CS, SoftPanel, MGD) ( Supplementary Fig. 10 ). In conclusion, TWAS across 58 traits shows that, compared to PrediXcan, EpiXcan has more 20 power to detect significant genes, including novel and unique associations, which are indispensable for life and clinically significant. In the following section, we further explore the EpiXcan-derived GTAs, in terms of: (1) per-tissue contribution of significant genes, (2) gene-set enrichment analysis, (3) computational drug repurposing analysis, and (4) genes shared within and across different disease categories.
Contribution of Tissues to the Identification of Associated Genes
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In this study we employ 3 different training cohorts to generate 14 predictive models for 8 tissue homogenate types and use the predictive models to impute tissue-specific transcriptomes across 58 GWASs. We first determine the robustness of our method, by examining the z-score correlation for similar tissues within and across cohorts by pooling together imputed transcriptomes for each tissue from all traits. As expected, predictions are highly correlated when Overall, per tissue, the numbers are largely comparable between consortia ( Supplementary Fig.  11 ). However, trait-relevant tissue models contribute disproportionately more gene-trait associations than non-relevant tissues (Fig. 3b) . For example, we find a higher number of contributions than the average of other tissues from brain tissue in schizophrenia, from arterial 10 tissues in cardiovascular disease, and from liver in lipid traits, respectively, which is concordant with previous Summary-data-based Mendelian Randomization analysis 6 . For 48 of the traits, more than 50% of the associated genes are only found in one tissue (Supplementary Fig. 12 ) and a large proportion (32.98% ± 17.36%; mean ± SD) of these unique GTAs come from the highest contributing tissue type (Supplementary Fig. 13) Fig.  14 , multiple linear regression model, p value = 0.007), indicating that additional GTAs will be uncovered with increased sample size of gene expression datasets in disease-relevant tissues. 25 GTAs for a given trait are enriched for genes implicated in diseases with more severe traitspecific phenotypes driven by larger effect mutations in those genes (ClinVar: λ = 1.83, p value = 7.07 × 10 -14 ; SoftPanel: λ = 1.36, p value < 2.22 × 10 -16 ; OMIM CS: λ = 1.29, p value = 6.17 × 10 -14 ; Supplementary Fig. 15 ). We also observe enrichment (λ = 1.21, p value = 1.69 × 10 -13 ) 30 for genes that produce mouse phenotypes in the same phenotypic category of the human trait when the mouse ortholog gene is disrupted.
Biological relevance of gene-trait associations
We perform gene-set enrichment analysis for the traits with more than 10 significant GTAs (43 out of 58 traits) to determine if the associated genes can be mapped to biological processes 35 (Supplementary Table 6 ). After FDR adjustment, 74 highly enriched pathways are obtained with p values < 1.70 × 10 -5 (corresponds to q < 0.05). Significantly associated genes are enriched for biological processes relevant to trait pathophysiology. For instance, the enriched pathways for elevated total cholesterol and triglycerides are involved in sterol and lipid homeostasis as well as lipoprotein digestion, mobilization, and transport. Similarly, for atopic dermatitis, the 40 significantly enriched pathway modulates the rate or extent of water loss from an organism via the skin. Genes associated with mineral density of the femoral bone demonstrate a high enrichment for a pathway that positively regulates cartilage development.
Leveraging gene-trait associations for computational drug repurposing
Computational drug repurposing offers a systematic approach for relating disease and druginduced states towards the goal of identifying novel indications for existing therapeutics 33 . We perform a computational screen against a library of 1,309 drug-induced transcriptional profiles 34 5 to identify small molecules capable of perturbing the expression of our identified trait-associated genes (Fig. 4a) . For each trait /compound pair, we calculate a signed "connectivity score" 34 , which summarizes the transcriptional relationship between each trait and drug signature, thus identifying drugs that might be predicted to "normalize" the gene-trait signature, as well as those expected to induce a "disease-like" state ( Fig. 4b-d, Supplementary Table 7) . Fig. 4e provides   10 example compounds predicted to regulate the expression of genes associated with the "Hip circumference adjusted BMI" trait. This list includes drugs under investigation for treatment of obesity, including ursolic acid, which is reported to increase skeletal muscle and brown fat while reducing diet induced obesity 35 . To explore the higher-level biological context for trait/compound associations, we perform a 15 chemogenomic enrichment analysis to determine whether drugs that regulate particular sets of trait-associated genes might share pharmacological features, such as drug targets, drug classes and side-effects (Fig. 4b) . We find multiple significant (FDR < 0.1) chemogenomic trends, including enrichments with phenotypically related side-effects (Fig. 4f) , supporting the potential for these compounds to perturb trait-related molecular networks. We hypothesized that, in general, trait-associated drug targets would connect to risk-associated 10 genes for phenotypically related diseases 36 . To evaluate this, we identify referenced 37 and predicted 38 drug targets that are enriched (FDR < 0.1) among compounds that modulate the signature of each trait. We identify ≥ 1 drug target enrichment, for 53 of the traits considered, and ≥ 3 drug targets for 40 traits (Supplementary Table 7) . We then perform a further gene set analysis on the targets associated with each trait, focusing on disease risk genetic resources that 15 might implicate phenotypes that could then be related to the traits considered within this study. We identify several significant overlaps (FDR < 0.1) between trait associated targets and phenotypically related disease risk gene sets (Fig. 4g, Supplementary Table 7 ). For example, drug targets enriched among compounds that perturb genes associated with "Hip circumference adjusted BMI" are enriched for risk genes for weight gain, nausea, and psychological stress, and 20 drug targets enriched among compounds that perturb "Coronary Artery Disease" associated genes are enriched for risk genes for heart disease, hypercholesterolemia, abdominal obesity, and myocardial infarction. Taken together, these chemogenomic enrichments illustrate the potential for the approach described in this study to inform drug discovery and drug development efforts. The identification 25 of side-effect and drug target enrichments linked to known or plausible trait biology supports the veracity of the repurposing predictions, and, more broadly, the power of integrative genomics approaches to identify novel molecular networks that underpin disease. 
Trait-trait correlations and gene-trait associations
To further understand the trait relatedness, we construct a network based on pairwise trait comparison of genetically regulated expression (GReX) (including traits with more than 50 significant associations). By using a broad categorization of traits (Supplementary Table 4) , we identify 245 pairs of shared gene associations across trait categories and 66 pairs within trait 35 categories (Fig. 5a, Supplementary Table 8 ). Higher numbers of genes are shared between traits that belong to the same trait category than traits belonging to different trait categories; the highest number of genes are shared between low density lipoprotein and total cholesterol in the "lipids" category. Previous studies have shown significant genetic correlation among common traits 39, 40 . Pairwise trait GReX correlation shows a positive association with genetic co-40 heritability 39,40 (Pearson's r = 0.8, p value < 2.79 × 10 -126 ) (Fig. 5b) , extending the genetic similarity among traits to specific genes.
We then apply bi-directional regression analyses 41 on the GReX of different traits across all tissues to infer causal relationships among pairs of traits with significant genetic and GReX 45 correlation (Fig. 5c for CAD and Supplementary Fig. 16 for all the traits in our study). We find evidence that CAD is a complex trait whose predicted gene expression changes can be partly, but directly, explained by predicted expression changes found in individuals with elevated triglycerides, elevated LDL, and increased waist/ hip ratio. On the other hand, predicted expression changes in individuals with increased HDL, or those suffering from ulcerative colitis (UC), are expected to normalize expression changes in individuals with CAD. By expanding the 5 causal network to include more upstream traits, we can see that another 6 traits (waist and hip circumference, years of education, age at menarche, birth weight, and BMI), which are correlated, or anti-correlated, with CAD may cause, or protect, from the predicted expression changes through effects on intermediate traits. For example, waist circumference acts via a causal relationship with triglycerides; other traits follow multiple pathways such as age at 10 menarche, which opposes predicted transcriptomic changes of the increased triglycerides group while promoting imputed transcriptomic changes for individuals with high HDL. We then leverage these causal networks to dissect the pathogenesis of CAD by identifying the molecular pathways shared among all the involved trait pairs. For each trait that can cause or protect from CAD, we identify the "agonistic" genes -genes whose predicted expression is changing towards 15 the same or opposite direction for causal (e.g. triglycerides) and protective (e.g. HDL) traits, respectively. Gene set enrichment analysis of agonistic genes for biological pathways point towards biologically relevant processes for CAD (Fig. 5d) . For example, a subset of CAD genes (n= 256 out of 2806 genes with p value ≤ 0.05) is shared with triglycerides and affects biological processes related to apolipoprotein binding and lipid digestion, mobilization and transport. Supplementary Fig. 16 ); nodes that are more times parent and child nodes are a darker shade of red and blue, respectively. In edges, width denotes absolute beta, redder color denotes lower p value, and the 2x or 3x labels denote that the relationship is identified in 2 or 3 tissues, respectively. The analysis is based on genes with FDR Taken together, the pairwise GReX trait correlations illustrate the potential to identify genes that are shared among genetically correlated traits. Agonistic versus antagonistic pleiotropy among two traits can be differentiated by leveraging the directionality of gene expression association in each trait. For traits, such as CAD, this analysis can be applied to dissect the complex phenotype, to identify genes and pathways that are shared with another trait, and potentially identify and develop therapeutic strategies to reverse those perturbations.
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Discussion
The maps of gene expression and regulatory annotations, generated by projects such as REMC 18 , CommonMind 21 , GTEx 23 , and STARNET 22 hold the potential to further our understanding of non-coding risk genetic variation. Here we describe EpiXcan which, compared to PrediXcan, 10 integrate biologically relevant data in a single framework to improve predictive performance of transcriptome imputation. EpiXcan is also better powered to identify clinically significant results such as enrichment for loss-of-function intolerant genes in neuropsychiatric traits 31, 32 and can detect more robust gene expression changes in genes associated with severe forms of the trait. We apply EpiXcan prediction models from 14 tissues in 58 common and complex traits and , we highlight the need for trait-relevant tissue datasets for such studies to be more effective. Second, among genes associated with the traits in this study, we observe significant enrichment for biological pathways involved in trait pathophysiology. Moreover, gene-trait associations are significantly enriched for: (1) pathogenic (or likely pathogenic) genes for the given trait (clinVar), (2) genes associated with trait-relevant 25 phenotypes (SoftPanel), (3) genes that have been associated with clinical signs relevant to the trait (OMIM CS), and (4) ortholog mouse genes with phenotypes that belong to the same phenotypic category as the given trait. This suggests that common variants partly act via smaller effect size perturbations in genes that lead to more severe forms of the phenotype when subject to larger effect size disruptions, as recently similarly suggested 42 . 30 Third, by leveraging trait-specific transcriptomic changes, we identify known and novel compounds that can reverse trait-specific changes, pointing to potential drug repurposing candidates. To our knowledge, there is only one recent study 43 that applied a similar approach but it was much more limited in scope (brain tissue -10 regions -transcriptomic imputation with 35 S-PrediXcan for psychiatric traits) and did not yield any statistically significant results for schizophrenia. In contrast, our study identifies one statistically significant result (phenformin, Supplementary Table 7 ) that is a very potent antidiabetic agent (no longer FDA-approved due to safety concerns) which is not surprising given that glucose homeostasis is altered from illness onset in schizophrenia 44 . Within the top 10 results for schizophrenia we also identify a potent 40 antipsychotic (prochlorperazine), a voltage-gated sodium channel 45 inhibitor (pramocaine) and guanfacine which was trialed for cognitive impairment in schizophrenia and found to be worthy of further investigation in order to target spatial working memory and continuous performance test reaction time for patients on atypical neuroleptics 46 . It is hard to directly compare the results of the two studies since our approaches differ on many levels: we use EpiXcan, train models on different tissues and more tissue types, and employ a different drug repurposing pipeline. Towards validating our approach, chemogenomic enrichment analysis reveals trait-specific, phenotypically related, side-effects and drug target enrichment for risk associated genes of phenotypically related traits. 5 Finally, we use bi-directional regression analysis 41 to construct putative causal trait networks. Causal trait networks built on top of EpiXcan are sufficiently powered to provide valuable insight into the development of complex traits such as CAD. For example, we find that high BMI can influence CAD by two distinct pathways; (a) by positively influencing triglycerides (TG) 10 which would positively influence CAD, and, conversely, (b) by negatively influencing HDL which would negatively influence CAD. The independent effect of BMI on TG and HDL has been shown in a population with a broad spectrum of BMI values 47 which -as in our studyfound no effect of BMI on LDL levels. Downstream, there is genetic evidence to suggest a causal influence of TG on CAD 48 . In addition, a negative correlation of HDL with CAD has been 15 established in observational epidemiology, although a link between genetic loci causal for high levels of HDL and protective for CAD is, at present, elusive 49 . The construction of these causal trait networks allows us to identify genes, among causally-linked traits, that exhibit agonistic pleiotropy participating in shared pathways. Such information could potentially be used to develop distinct therapeutic strategies based on individual comorbidities. 20 Overall, the described method utilizes epigenomic information to further improve prediction of transcriptomes and it provides a framework for TWASs, improved interrogation of traitassociated biological pathway involvement, and a platform for drug repurposing and treatment development. 25 To facilitate interpretation, we provide the EpiXcan pipeline, trained models and resulting data tables as an online resource.
Genotype datasets (CMC, GTEx and STARNET) are uniformly processed for quality control (QC) steps before imputation. We restrict to samples with European ancestry (Supplementary methods). Genotypes are imputed using the University of Michigan server 50 with Haplotype Reference Consortium (HRC) reference panel 51 . RNAseq gene level counts are adjusted for known and hidden confounds, followed by quantile normalization. For CMC gene 35 expression, we use the gene level counts generated from DLPFC RNAseq data 21 (http://commonmind.org/). For GTEx 52 , we use publicly available quality-controlled gene expression datasets from GTEx consortium (http://www.gtexportal.org/). RNAseq data for STARNET were generated as described in Franzén integrated to obtain SNP priors using qtlBHM 20 (top panel in Supplementary Fig. 1 ; Supplementary Materials and Methods; Supplementary Table 9) . Lastly, the SNP priors are rescaled to penalty factors used in WENet by a data-driven rescaling equation. The optimal rescaling equation is approximated by the best performing quadratic Bézier function, providing both the curve of the rescaling function and the minimum value of the penalty factors. Briefly, to determine the best performing rescaling equation, we simulate genotypes (n=500 samples) using 5 HAPGEN2 54 and haplotypes from the 1000 Genomes Project 55 . For each gene under consideration, we utilize a shifting window policy to generate quadratic Bézier rescaling equations. In each separate window, we define a minimal penalty factor (Supplementary Fig. 17 ) and within that window we evaluate possible intermediate Bézier curve control point locations to test for a wide range of curves for our rescaling equation (Supplementary Fig. 18 ). The equation that exhibits the highest improvement of R 2 CV when compared to not assigning penalty factors to the 10 SNPs (as in PrediXcan) is selected. The process to evaluate and select the optimal rescaling equation is described in greater detail in Supplementary Methods. 
Simulation analysis to compare EpiXcan and PrediXcan predictive performance
Here 'ൈ' denotes matrix-vector product and ߳ is normally distributed noise with given standard deviation (SD=0.3). We select ten levels (Level from 0.1 to 1) of noise to simulate expression values for given genes. The CMC eQTL 20 beta values are used as the effects in the simulation. We use 1,000 genes with the highest significance from CMC eQTL studies to perform the simulations. Table 4 ) and gene expression predictors using S-PrediXcan 42 . SNPs in the broad major histocompatibility complex (MHC) region 30 (chromosome 6: 25~35 Mb) are removed. P values are adjusted using the Benjamini-Hochberg method of controlling the false discovery rate at 0.01. The gene-trait associations that remain after this filtering are considered "significant".
Enrichment score: We use an enrichment score 6 to indicate enrichment or depletion of the trait in a given tissue. For 35 each tissue-trait combination, we count the number of genes that are significantly associated with the trait in that tissue (n tissue,trait ) and divide them by the number of all the genes that had a prediction either significant or not (t tissue,trait ):
. To scale the normalized count N tissue,trait we first subtract the mean normalized count for all tissues for the given trait N trait and then divide the result by the standard deviation (SD) of the normalized count for all tissues for the given trait:
. In Fig. 3b , e tissue,trait is used as the enrichment 40 score for depicted by the color scale.
Unique associations: Uniquely identified genes by EpiXcan (or PrediXcan) are genes that are identified in significant gene-trait associations with one method but not the other. For gene-trait associations found in multiple tissues, we categorize genes as up-(or down-) regulated in the trait if there are more tissues in which the effects are 45 towards the indicated direction. If there are equivalent numbers of tissues in which the gene is positively and negatively correlated with a given trait, we categorize the gene regulation as ambiguous. Transcriptomic imputation yields approximately the same number of genes predicted to be up-or downregulated (z-scores) across each trait (Supplementary Fig. 19 ). To construct the shared gene network in Fig. 5a : (1) Table 5 ). The phenotypic datasets: ClinVar, OMIM CS, SoftPanel, and MGD are prepared as described in Supplementary Methods and contain genes that are associated with one or multiple traits. The approximation of known genephenotype associations from these datasets allows us to (1) compare the power of EpiXcan vs. PrediXcan in identifying known gene-trait associations (as in Fig. 2d ) and (2) evaluate the extent to which common risk variants 25 confer trait risk by affecting gene expression levels of genes associated with monogenic forms of the trait or genes associated with similar-to-the-trait phenotypes in humans and mice.
Computational drug repurposing 30 We iterated over each trait considered in this study, retaining trait/gene associations with an FDR < 0.1, and converting HGNC gene symbols to NCBI entrez gene identifiers. If a gene is linked with a trait via an association detected in multiple tissues, the associations are summarized as the mean z-score. There are 58 traits with a minimum of 5 positively, and negatively, associated genes and each of these are used as the basis for drug repurposing. For each of these traits, and for each unique compound, we calculate a "connectivity score" based on a 35 modified Kolmogorov-Smirnov score 34 , which summarizes the transcriptional relationship to the trait-associated genes. We estimate statistical significance by generating an empirical Kolmogorov-Smirnov score distribution from the query signature against 1,000 permuted drug signatures. Compound profiles are sourced from Connectivity map 34 . We download and merge the 6,100 individual experiments into a single representative signature for the 1,309 unique small molecule compounds according to the prototype-ranked list method 58 . 40
Chemogenomic enrichment analysis: For each trait, connectivity scores are then used to sort the list of 1,309 compounds and used as the basis for a chemogenomic enrichment analysis. For each compound in the drug signature library, we collect diverse chemogenomic annotations, such as drug target information, side-effect, and therapeutic class associations. Side-effect associations are downloaded from Offsides 59 and SIDER 59 and connected 45 to compounds in Connectivity map via Stitch identifiers. Drug target associations include targets referenced in DrugBank 37 , and also an augmented set of associations, based on predictions generated using the Similarity Ensemble Approach 38 . For each of these features, we calculate a signed running sum enrichment score, which reflects whether that feature is over-represented at the extreme ends of the drug list that has been ordered according to trait. Statistical significance of enrichment scores is based on comparison to a large distribution of permuted null 50 scores, generated by calculating scores from randomized chemogenomic sets that contain an equivalent number of compounds to the true set being evaluated. p values are adjusted using the Benjamini-Hochberg method of controlling the false discovery rate. . We use a Fisher's exact test to compare each set of trait-associated drug targets (that contain at least 3 targets), with each disease risk gene set. The analysis is performed against a background of 2,802 genes, 5 representing the unique set of human drug targets in the combined set of referenced and predicted targets associated with the 1,309 compounds. Two-sided p values are adjusted using the Benjamini-Hochberg method of controlling the FDR.
Trait co-heritability analysis
10
Tissue clustering: To calculate the genetically regulated gene expression correlation (r GReX ), as shown in Fig. 3a , we keep the significant imputed gene expression change (z score) values with q value 0.01 and perform pairwise tissue Spearman correlation analysis of the complete cases of z scores. To cluster the tissues together for plotting, we use hierarchical agglomerative clustering analysis with Ward's method. 15 Genetically regulated gene expression correlation (r GReX ): Pairwise genetic correlation (r g ), as shown in Fig. 5b , among traits analyzed by GWAS is taken from previously published reports 39, 40 . For trait comparisons that appear in both studies we use the more recent study 40 . We consider the genetic correlation between traits significant if q value 0.05. To calculate r GReX , we keep the imputed gene expression values with unadjusted p value 0.05 and 20 perform pairwise trait Spearman's correlation analysis with Holm's adjustment for multiple comparisons. To estimate the correlation of r g and r GReX for the trait pairs in our study we perform Pearson's correlation analysis with Holm's adjustment for multiple comparisons.
Bi-directional regression and exploratory pathway analyses for putatively causally linked traits: We identify all the 25 significantly correlated trait-pairs (r g and r GReX , q value 0.05 as above) and perform bi-directional regression analyses 41 to identify causal relationships among the traits of our study (Supplementary Fig. 16 ). Then taking as an example the coronary artery disease (CAD), we graph all the putative causal and protective relationships up to 2 nodes upstream in Fig. 5c (when the causal relationship is bi-directional between 2 traits, the relationship with the higher degrees of freedom is kept) and perform pathway enrichment analysis of shared agonistic genes for this 30 causal network in Fig. 5d . For each causal or protective trait in the network, we generate a list of genes whose expression changes are predicted towards the same direction (or the opposite direction for protective traits) in CAD. These lists of shared "agonistic" genes are used for GSEA for common pathways. In Fig. 5d . only the top 15 (based on q value) results are shown and are ranked based on odds ratio. 
